Gladstone Institutes

Patented compositions and methods for reactivating latent immunodeficiency virus.

Patented compositions and methods for regulating glucose metabolism.

Patented compositions and methods for treating neurological disorders.

Patented compositions and methods for treating dengue virus infection.

Patented methods for modulating genome editing processes.

Patented methods for inducing cardiomyogenesis.

Patented methods for reactivating latent HIV using cytosine methylation inhibitors and NF-ΚB activators.

Patented methods for treating cytomegalovirus infection.

Patented methods for treating lentivirus infections.

Patented methods and compositions for producing pancreatic beta cells.

Patented methods and compositions for synergistic activation of latent HIV.

Patented methods and compositions for reducing amyloid beta levels.

Patented methods and compositions for treating obesity and diabetes and identifying treatment agents.

Patented methods for modulating smooth muscle cell proliferation and differentiation.

Patented methods for modulating lipid concentrations in eukaryotic cells.

Patented methods for treating neurodegenerative diseases.

Patented methods for treating diseases by controlling T-cell differentiation metabolically.

Patented methods for treating smooth muscle cell disorders.

Helps scientists establish new assays or adapt existing ones for high-throughput screening, accelerating research into target and drug-discovery phases and moving findings into clinical trials.

Provides flow cytometry and cell-sorting services with assistance in experiment design, data analysis, and technical guidance.

Cell sorting for up to 18 fluorescent parameters with 5 available lasers and functional marker sorting and analysis, including single-cell sorting into 96-well plates for cloning or further sequencing downstream analysis.

Provides state-of-the-art genomic and sequencing services to support basic and translational medical research for academic institutions and industry sectors, enabling cost-effective, customized genomic analyses.

Provides space, equipment, reagents, scientific training, and services for stem cell research, including availability of wildtype and CRISPR-modified (iPS) cell lines for purchase.

Supports a wide range of projects investigating complex behavioral functions related to neurological and psychiatric diseases, helping unravel neurobiological pathways, validate therapeutic targets, and assess treatment efficacy.

Analysis of up to 40 fluorescences in one tube, including extra, intracellular and functional markers as well as fluorescent proteins, with high-throughput analysis from 96- and 384-well plates.

Provides expertise on experimental design and data analysis of complex data sets, specializing in large-scale data from cutting-edge technologies, including sequence analysis, pathway and network analysis, and data integration.

High-throughput sequencing system used for genomic sequencing at the Gladstone Genomics Core.

Custom library preparation services for DNA/RNA-seq, SMART-seq, Amplicon seq, PacBio SMRT seq, CRISPR-based single-cell screens, and more.

Sequencing system for genomic applications available at the Gladstone Genomics Core.

Service to generate transgenic animals by injecting plasmid or BAC DNA into mouse embryos of C57BL/6 or FVB/n strains.

The core injects or electroporates CRISPR reagents into C57BL/6 and FVB embryos to create knock-out and knock-in mice models.

Provides technical assistance, training, consultation, and collaboration in experimental design, sample preparation, image acquisition, processing, and quantitative data analysis with expertise in various microscopy techniques and tissue clearing.

A high-throughput live-cell imaging system used for advanced analysis in stem cell-based disease modeling and drug screening.

Sample preparation including nucleic acid extraction, DNA/chromatin shearing, Bioanalyzer analysis, nucleic acid quantitation by Qubit and qPCR.

Liquid handling system with 96 well pipette heads for small and larger volumes, 9 decks including plate shaker, and 4 plate-stacking racks. Used for stamping library daughter plates, adding reagents to 96 or 384-well plates, making serial dilutions, and thermally sealing microplates.

A benchtop single-cell dispenser enabling easy single-cell sorting into 96- or 384-well plates for applications including genomics analysis, cloning, and cell line development.

Compact sequencing system for genomic sequencing applications.

Provides state-of-the-art technology to characterize protein dynamics in biological systems, including proteomics approaches like protein-protein interaction characterization, complex protein mixture analysis, quantitative protein abundance analysis, and post-translational modification characterization.

Imaging cytometry for up to 6 fluorescences, or 4 fluorescences including brightfield and side scatter, with magnifications of 20X, 40X and 60X.

An imaging system used for high-throughput imaging in stem cell research and drug screening applications.

10x Genomics's latest single-cell instrument designed to scale up single-cell experiments, providing a complete single-cell system for expanded profiling and increased sample sizes.

Testing of human induced pluripotent stem cells (hiPS cells) for expression of a panel of pluripotent markers to define their pluripotency status, with a turnaround time of approximately 1 day and delivery of all raw data files.

Multiparameter characterization, sizing and concentration analysis of natural and synthetic nanoparticles (7-1000 nm) at the single-particle level, including detection of extracellular vesicles, mitochondria, bacteria, viruses, nanomedicine, nanomaterial and other nanoparticles.

Lab automation equipment used at the Gladstone-CIRM Shared Resources Laboratory to increase production and improve reproducibility in stem cell research and drug screening.

Faithful and robust cell-based high-throughput screening (HTS) platforms using primary neurons and human iPSC-derived neurons to model Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, and Huntington's disease for drug discovery.

Service to inject provided ES cell clones into blastocysts of day-3.5 embryos and transfer into recipient female mice to create chimeric mice.

A high-content confocal imaging system used for detailed cellular analysis in stem cell-based disease modeling and drug screening.

Lab automation equipment used at the Gladstone-CIRM Shared Resources Laboratory to support stem cell-based disease modeling and drug screening.

Plate reader using electrochemiluminescence detection technology with ultra-low detection limits, wide dynamic range, and multiplex panels for measuring up to ten analytes from a single sample. Suitable for biomarkers of inflammation, neurodegenerative diseases, cardiovascular and metabolic dysfunction, and infectious diseases.

Liquid handling system for dispensing and aspirating liquids into 96 and 384 well plates in sterile environment with 8-channel cassettes. Used for dispensing cell suspensions and precoating plates.

Device used for single cell/nucleus partitioning in 10x Genomics single cell solutions.

A nanoparticle formulator used for nanoparticle formulation and characterization at the Gladstone-CIRM Shared Resources Laboratory.

A state-of-the-art mass spectrometer used for detailed biological discovery and quantitation in proteomics research.

Building next generation of target and drug discovery using live cell robotic microscopy imaging, AI-based tracking, and dynamical single-cell phenotyping for causal drug screens across disease progression.

Plate reader with colorimetric, fluorescence, and luminescence readouts for 96 and 384-well microplates. Set up for colorimetric, fluorescence and Luciferase assays with specific fluorescence filters.

Patented methods for generating neural stem cells.

Automated high-content imaging system for cell-based assays.

Next-generation molecular profiling solution for spatial transcriptomics on FFPE and fresh-frozen tissues, providing holistic understanding of gene expression in tissue microenvironment.

Technology for generating expandable cardiovascular progenitor cells.

Technology for reverting primed pluripotent stem cells to naive pluripotent stem cells.

Liquid handling system with 96-well head to dispense and aspirate liquids, full plate washing and dispensing for ELISA assays and immunofluorescence staining for cell-based assays, and 8-channel cassettes manifold to dispense small amounts of liquid.

Patented virion-based fusion assay for research applications.

High-content microscope for cell-based assays and imaging.

A nanoparticle characterizer used for nanoparticle formulation and characterization at the Gladstone-CIRM Shared Resources Laboratory.

Instrument for nucleic acid quality control and analysis.

Patented methods for generating definitive endoderm and pancreatic progenitor cells.

Patented methods for generating hepatocytes for research and therapeutic use.

Patented method for identifying agents that inhibit APOBEC3C activity in HIV-infected cells.

Real-time PCR detection system used for nucleic acid quantitation and analysis.

Patented in vitro methods for differentiating stem cells into neurons and the neurons generated by these methods.

Refining techniques to produce neurons from stem cells to replace those lost during Alzheimer’s disease. Backed by venture capital and actively fundraising for Series A investment.

Patented mouse model for chronic heart failure and coronary atherosclerosis regression research.

A patented dual-color HIV reporter system for detecting latently infected cells.

Spectrophotometer for nucleic acid quantitation and quality assessment.

Patented compositions, systems, and methods for gene expression noise drug screening and related uses.

Developing therapies to permanently repair the heart after damage using the heart’s own cells to reverse heart failure effects and novel gene therapy. Raised significant financing and initiated Phase I clinical trial.

Develops small molecule therapeutics for treating Alzheimer’s disease targeting reduction of the protein tau. Founded as a joint venture with initial $5 million investment, raised over $19 million in funding.

A retron-based gene-editing therapeutics company founded in 2022, currently in stealth mode with initial $10 million raise.

Patented method for increasing cathepsin B-induced cleavage of amyloid-beta peptides.

Focuses on prevention of SARS-CoV-2 by hijacking viral replication system using Therapeutic Interfering Particles (TIPs) technology—single-administration, resistance-proof, non-replicating viral particles developed at Gladstone.

Patented methods for detecting neurological disorders.

Focuses on fibrin, a blood protein linked with neuroinflammation, and invents an antibody to selectively target this protein. Financed with seed rounds totaling $26 million.

Patented methods for promoting CNS neuronal repair by inhibiting LRP-1.

Patented use of SIRT1 activators or inhibitors to modulate immune response.

Patented immunogenic compositions comprising HIV-1 acetylated Tat polypeptides.

Patented methods for treatment of HIV-1 infection and AIDS.

Patented enzyme diacylglycerol O-acyltransferase 2 alpha (DGAT2α).

Patented enzyme Acyl CoA: Cholesterol Acyltransferase (ACAT-2).

Patented substituted benzoxazine and related compounds for therapeutic use.

Patented histone deacetylase enzyme and methods of use.